Aptinyx to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021

Rhea-AI Summary

Aptinyx Inc. (Nasdaq: APTX) will host a conference call on May 13, 2021, at 5:00 p.m. ET to discuss its first-quarter 2021 financial results and recent business highlights. The call is accessible by dialing (833) 772-0394 domestically or (236) 738-2205 internationally, using conference ID 3628539. A live audio webcast will also be available on the company’s website, with a replay archived for 30 days. Aptinyx focuses on developing therapies for brain and nervous system disorders using a unique mechanism to enhance synaptic plasticity.

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, May 13, 2021 at 5:00 p.m. ET to report first quarter 2021 financial results and discuss recent business highlights.

To access the live conference call, please dial (833) 772-0394 (domestic) or (236) 738-2205 (international) and refer to conference ID 3628539. A live audio webcast of the event will be available on the Investors & Media section of Aptinyx’s website at https://ir.aptinyx.com. A replay of the webcast will be archived on Aptinyx’s website for 30 days following the event.

About Aptinyx

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com.

Source: Aptinyx Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210429005212/en/

FAQ

When will Aptinyx report its first quarter 2021 financial results?

Aptinyx will report its first quarter 2021 financial results on May 13, 2021, at 5:00 p.m. ET.

How can I access the Aptinyx conference call?

You can access the conference call by dialing (833) 772-0394 domestically or (236) 738-2205 internationally, using conference ID 3628539.

Where can I watch the Aptinyx conference call live?

The conference call will be available as a live audio webcast on the Investors & Media section of Aptinyx's website.

What diseases is Aptinyx developing treatments for?

Aptinyx is developing treatments for brain and nervous system disorders, including chronic pain, PTSD, and cognitive impairment.

How long will the recording of the conference call be available?

The recording of the conference call will be archived on Aptinyx's website for 30 days following the event.